Early stage nonclinical pulmonary disorder in COVID-19 may present asymptomatic and fuel the contagion  

作　　者：Kamoru Ademola Adedokun 

机构地区：[1]Oral Pathology Unit,Dental University Hospital,King Saud University Medical City,Riyadh 11545,Saudi Arabia

出　　处：《Military Medical Research》2021年第4期584-586,共3页军事医学研究（英文版）

摘　　要：Evidence shows that pulmonary problems in coronavirus disease 2019(COVID-19)may set off from vascular injury that progresses to physiological disturbances through a compromised gas exchange,following an infection with the severe acute respiratory syndrome coronavirus 2.In this process,inefficient gas exchange in the alveolar could precipitate silent nonclinical hypoxemia.Unfortunately,patients with“silent hypoxemia”do not necessarily experience any breathing difficulty(dyspnea)at the early stage of COVID-19 while the disease progresses.As a result,several asymptomatic,presymptomatic and patients with mild symptoms may escape quarantine measure and thus continue to spread the virus through contacts.Therefore,early diagnosis of“silent hypoxemia“,which attracts no clinical warnings,could be an important diagnostic measure to prevent acute respiratory distress syndrome from the risk of pulmonary failure among the presymptomatic and as a screening tool in the asymptomatic who are hitherto potential spreaders of the virus.

关 键 词：Acute respiratory diseases Coronavirus disease 2019 DYSPNEA Gas exchange OXIMETRY Pulmonary disorder Severe acute respiratory syndrome coronavirus 2 Silent hypoxemia 

分 类 号：R563.1[医药卫生—呼吸系统]